225 related articles for article (PubMed ID: 28269771)
21. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.
Pan C; Korff A; Galasko D; Ginghina C; Peskind E; Li G; Quinn J; Montine TJ; Cain K; Shi M; Zhang J
J Alzheimers Dis; 2015; 45(3):709-19. PubMed ID: 25613100
[TBL] [Abstract][Full Text] [Related]
23. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J
J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy.
Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D
J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960
[TBL] [Abstract][Full Text] [Related]
25. Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.
Berge G; Lauridsen C; Sando SB; Holder DJ; Møller I; Aasly JO; Bråthen G; Savage MJ; White LR
J Alzheimers Dis; 2016; 49(2):493-502. PubMed ID: 26484901
[TBL] [Abstract][Full Text] [Related]
26. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
[TBL] [Abstract][Full Text] [Related]
27. Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers.
Leitão MJ; Baldeiras I; Herukka SK; Pikkarainen M; Leinonen V; Simonsen AH; Perret-Liaudet A; Fourier A; Quadrio I; Veiga PM; de Oliveira CR
Front Neurol; 2015; 6():153. PubMed ID: 26217300
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
[TBL] [Abstract][Full Text] [Related]
29. Influence of kidney function and CSF/serum albumin ratio on plasma Aβ42 and Aβ40 levels measured on a fully automated platform in patients with Alzheimer's disease.
Verde F; Milone I; Dubini A; Colombrita C; Perego A; Solca F; Maranzano A; Ciusani E; Poletti B; Ratti A; Torresani E; Silani V; Ticozzi N
Neurol Sci; 2023 Sep; 44(9):3287-3290. PubMed ID: 37284933
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.
Shoji M
Front Biosci; 2002 Apr; 7():d997-1006. PubMed ID: 11897565
[TBL] [Abstract][Full Text] [Related]
31. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau.
Hansson O; Batrla R; Brix B; Carrillo MC; Corradini V; Edelmayer RM; Esquivel RN; Hall C; Lawson J; Bastard NL; Molinuevo JL; Nisenbaum LK; Rutz S; Salamone SJ; Teunissen CE; Traynham C; Umek RM; Vanderstichele H; Vandijck M; Wahl S; Weber CJ; Zetterberg H; Blennow K
Alzheimers Dement; 2021 Sep; 17(9):1575-1582. PubMed ID: 33788410
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
[TBL] [Abstract][Full Text] [Related]
33. Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App
Andersson E; Schultz N; Saito T; Saido TC; Blennow K; Gouras GK; Zetterberg H; Hansson O
Alzheimers Res Ther; 2023 Mar; 15(1):64. PubMed ID: 36964585
[TBL] [Abstract][Full Text] [Related]
34. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
35. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.
Tapiola T; Pirttilä T; Mikkonen M; Mehta PD; Alafuzoff I; Koivisto K; Soininen H
Neurosci Lett; 2000 Feb; 280(2):119-22. PubMed ID: 10686392
[TBL] [Abstract][Full Text] [Related]
36. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.
Rozga M; Bittner T; Höglund K; Blennow K
Clin Chem Lab Med; 2017 Aug; 55(10):1545-1554. PubMed ID: 28160541
[TBL] [Abstract][Full Text] [Related]
38. Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein.
Mizoi M; Yoshida M; Saiki R; Waragai M; Uemura K; Akatsu H; Kashiwagi K; Igarashi K
Clin Chim Acta; 2014 Mar; 430():150-5. PubMed ID: 24508996
[TBL] [Abstract][Full Text] [Related]
39. How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ
Willemse E; van Uffelen K; Brix B; Engelborghs S; Vanderstichele H; Teunissen C
Alzheimers Dement; 2017 Aug; 13(8):885-892. PubMed ID: 28222302
[TBL] [Abstract][Full Text] [Related]
40. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.
Korecka M; Figurski MJ; Landau SM; Brylska M; Alexander J; Blennow K; Zetterberg H; Jagust WJ; Trojanowski JQ; Shaw LM;
Clin Chem; 2020 Apr; 66(4):587-597. PubMed ID: 32087019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
